News
Public · Published
RVTY: Q3 growth accelerated to 7%, lifting FY26 guidance as AI and market recovery broaden demand
Revvity reported third-quarter pro forma organic growth of 7%, helped by strength in Life Sciences, improving demand from pharmaceutical and biotech customers, and early AI-driven demand. The company raised its full-year growth and margin guidance and now expects adjusted earnings per share of $5.40 to $5.45.
Published:
Updated:
What happened
Revvity reported third-quarter pro forma organic growth of 7%, helped by strength in Life Sciences, improving demand from pharmaceutical and biotech customers, and early AI-driven demand. The company raised its full-year growth and margin guidance and now expects adjusted earnings per share of $5.40 to $5.45.
Confirmed
Global impact / market context
Faster sales growth plus a higher profit outlook means Revvity is selling more and keeping more profit per sale. That can support future cash available for research, debt repayment, or buybacks, and it signals that demand from drugmakers and biotech labs is recovering.
Analyst inference
Life-science tool makers depend on spending by drug and biotech labs. Improving pharma-biotech demand and early AI-related orders suggest customers are restarting projects after a cautious stretch. If that continues, sales and profit can rise together, though AI demand is described only as early and may not last.
Analyst inference
What to watch
- Revvity now expects full-year adjusted earnings per share of $5.40 to $5.45, alongside higher growth and margin guidance, so future results should be compared with these raised targets. Confirmed
- Watch whether early AI-driven demand turns into repeat orders across more products, since that would show the trend is broadening rather than a one-off boost to sales. Proposed
- Track pharma and biotech research budgets next, because a pause in customer spending would slow orders for Revvity's lab tools and could put the raised guidance at risk. Analyst inference
Evidence
- Original source link unavailable